Lycia Therapeutics, Inc.
Lycia Therapeutics filed Amendment No. 1 to its S-1 registration for an IPO of 14.7 million shares at an estimated range of $16.00 to $18.00 per share, targeting gross proceeds of approximately $235 million to $265 million. The clinical-stage biotech is built around the LYTAC (Lysosomal Targeting Chimera) platform, which degrades extracellular disease-causing proteins, with lead programs in IgE-driven allergic diseases (LCA-0061, LCA-0062) and Graves' disease (LCA-0321). Preliminary Phase 1 data for LCA-0061 showed a 96% mean maximum IgE reduction from baseline with a single 70 mg SC dose.
- Offering 14.7M shares at $16.00–$18.00, targeting ~$235M–$265M in gross proceeds before greenshoe.
- LCA-0061 Phase 1 data showed mean maximum IgE reduction of 96% from baseline with a single 70 mg SC dose.
- Lead IgE degrader LCA-0061 and Graves' disease program LCA-0321 both expect initial clinical data in 2027.
- LCA-0062, a fast-follower bispecific IgE degrader, targets Phase 1 initiation and initial data in H2 2027.
- Xolair (omalizumab) surpassed $4B in U.S. annual sales by 2025, with over 100,000 food allergy patients prescribed.
Price data unavailable.
First pure-play extracellular protein degradation platform to file for IPO, with early but compelling human proof-of-mechanism data and a pipeline targeting multi-billion-dollar allergic and immunodys
The IPO arrives amid strong investor appetite for immunology platforms with clinical validation. Xolair's rapid food-allergy launch (>$4B U.S. sales, >100K patients by 2025) establishes a large addressable market. Lycia's degrader approach competes conceptually with FcRn inhibitors (e.g., argenx'sVy
No approved products; all candidates are clinical or preclinical. The LYTAC platform has only preliminary human proof-of-mechanism from a single cohort. The company is an emerging growth company with limited operating history and expects to incur substantial losses. IPO pricing and Nasdaq listing ("
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.